RS55870B1 - Hpn-100 za upotrebu u lečenju poremećaja nakupljanja azota - Google Patents
Hpn-100 za upotrebu u lečenju poremećaja nakupljanja azotaInfo
- Publication number
- RS55870B1 RS55870B1 RS20170421A RSP20170421A RS55870B1 RS 55870 B1 RS55870 B1 RS 55870B1 RS 20170421 A RS20170421 A RS 20170421A RS P20170421 A RSP20170421 A RS P20170421A RS 55870 B1 RS55870 B1 RS 55870B1
- Authority
- RS
- Serbia
- Prior art keywords
- paa
- dose
- ratio
- pagn
- hpn
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636256P | 2012-04-20 | 2012-04-20 | |
| EP12874745.8A EP2846791B1 (en) | 2012-04-20 | 2012-09-11 | Hpn-100 for use in the treatment of nitrogen retention disorders |
| PCT/US2012/054673 WO2013158145A1 (en) | 2012-04-20 | 2012-09-11 | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS55870B1 true RS55870B1 (sr) | 2017-08-31 |
Family
ID=49380684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20170421A RS55870B1 (sr) | 2012-04-20 | 2012-09-11 | Hpn-100 za upotrebu u lečenju poremećaja nakupljanja azota |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US9561197B2 (enExample) |
| EP (2) | EP2846791B1 (enExample) |
| JP (3) | JP6234436B2 (enExample) |
| KR (2) | KR102264579B1 (enExample) |
| CN (3) | CN113995743A (enExample) |
| AU (3) | AU2012377389A1 (enExample) |
| BR (1) | BR112014026138A2 (enExample) |
| CL (2) | CL2014002807A1 (enExample) |
| CY (1) | CY1118838T1 (enExample) |
| DK (1) | DK2846791T3 (enExample) |
| EC (1) | ECSP14024561A (enExample) |
| ES (2) | ES2623470T3 (enExample) |
| HR (1) | HRP20170651T1 (enExample) |
| HU (1) | HUE032726T2 (enExample) |
| IL (2) | IL235127A (enExample) |
| LT (1) | LT2846791T (enExample) |
| MX (1) | MX365302B (enExample) |
| PL (1) | PL2846791T3 (enExample) |
| PT (1) | PT2846791T (enExample) |
| RS (1) | RS55870B1 (enExample) |
| SG (2) | SG10201608749UA (enExample) |
| SI (1) | SI2846791T1 (enExample) |
| SM (1) | SMT201700219T1 (enExample) |
| WO (1) | WO2013158145A1 (enExample) |
| ZA (1) | ZA201407597B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3263102A1 (en) | 2011-09-30 | 2018-01-03 | Horizon Therapeutics, LLC | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| BR112014026138A2 (pt) | 2012-04-20 | 2017-06-27 | Hyperion Therapeutics Inc | métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético |
| HUE036133T2 (hu) | 2012-11-21 | 2018-06-28 | Horizon Therapeutics Llc | Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére |
| PL2986325T3 (pl) | 2013-10-14 | 2020-03-31 | Immedica Pharma Ab | Sposoby leczenia zaburzenia cyklu mocznikowego |
| ES2748294T3 (es) * | 2014-06-04 | 2020-03-16 | Immedica Pharma Ab | Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre |
| US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| US20190076383A1 (en) * | 2017-09-08 | 2019-03-14 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders |
| US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| US5879657A (en) | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
| WO1996024571A1 (en) | 1995-02-07 | 1996-08-15 | Brusilow Saul W | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders |
| US6219567B1 (en) | 1999-06-21 | 2001-04-17 | Cardiox Corporation | Monitoring of total ammoniacal concentration in blood |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US20050273359A1 (en) | 2004-06-03 | 2005-12-08 | Young David E | System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure |
| PT2319581E (pt) | 2004-11-26 | 2015-06-30 | Ucl Business Plc | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| US20070004805A1 (en) | 2005-07-01 | 2007-01-04 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
| US20100016207A1 (en) | 2005-11-10 | 2010-01-21 | Wurtman Richard J | Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid |
| US8094521B2 (en) | 2007-02-28 | 2012-01-10 | Nightingale Products LLC | Caregiver personal alert device |
| GB2451259B (en) * | 2007-07-25 | 2011-07-20 | Gp Acoustics | Loudspeaker |
| US9078864B2 (en) | 2008-01-08 | 2015-07-14 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| GB2465250B (en) * | 2008-08-29 | 2011-01-26 | Ucyclyd Pharma Inc | Dosing and monitoring patients on nitrogen-scavenging drugs |
| WO2009134460A1 (en) * | 2008-04-29 | 2009-11-05 | Hyperion Therapeutics | Methods of treatment using ammonia-scavenging drugs |
| JP5577341B2 (ja) * | 2008-08-29 | 2014-08-20 | ハイペリオン セラピューティクス， インコーポレイテッド | アンモニア捕捉薬を使用する処置方法 |
| CN102481269B (zh) * | 2009-05-11 | 2015-10-07 | 博格有限责任公司 | 包含辅酶q10的药物组合物及其制备方法 |
| EP2954780A1 (en) | 2009-07-24 | 2015-12-16 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
| JP6049619B2 (ja) | 2010-08-31 | 2016-12-21 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ナノヒドロキシアパタイトを含む多孔質多糖足場、及び骨形成のための使用 |
| EP3263102A1 (en) | 2011-09-30 | 2018-01-03 | Horizon Therapeutics, LLC | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| BR112014026138A2 (pt) * | 2012-04-20 | 2017-06-27 | Hyperion Therapeutics Inc | métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético |
| HUE036133T2 (hu) | 2012-11-21 | 2018-06-28 | Horizon Therapeutics Llc | Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére |
-
2012
- 2012-09-11 BR BR112014026138A patent/BR112014026138A2/pt not_active Application Discontinuation
- 2012-09-11 SI SI201230933A patent/SI2846791T1/sl unknown
- 2012-09-11 KR KR1020197029026A patent/KR102264579B1/ko active Active
- 2012-09-11 RS RS20170421A patent/RS55870B1/sr unknown
- 2012-09-11 SG SG10201608749UA patent/SG10201608749UA/en unknown
- 2012-09-11 KR KR1020147032114A patent/KR20150013170A/ko not_active Withdrawn
- 2012-09-11 CN CN202111191403.5A patent/CN113995743A/zh active Pending
- 2012-09-11 LT LTEP12874745.8T patent/LT2846791T/lt unknown
- 2012-09-11 US US13/610,580 patent/US9561197B2/en active Active
- 2012-09-11 PL PL12874745T patent/PL2846791T3/pl unknown
- 2012-09-11 AU AU2012377389A patent/AU2012377389A1/en not_active Abandoned
- 2012-09-11 EP EP12874745.8A patent/EP2846791B1/en active Active
- 2012-09-11 SM SM20170219T patent/SMT201700219T1/it unknown
- 2012-09-11 PT PT128747458T patent/PT2846791T/pt unknown
- 2012-09-11 SG SG11201406745VA patent/SG11201406745VA/en unknown
- 2012-09-11 CN CN201280074143.6A patent/CN104540507A/zh active Pending
- 2012-09-11 ES ES12874745.8T patent/ES2623470T3/es active Active
- 2012-09-11 HR HRP20170651TT patent/HRP20170651T1/hr unknown
- 2012-09-11 ES ES17154858T patent/ES2807951T3/es active Active
- 2012-09-11 HU HUE12874745A patent/HUE032726T2/en unknown
- 2012-09-11 EP EP17154858.9A patent/EP3222275B1/en active Active
- 2012-09-11 DK DK12874745.8T patent/DK2846791T3/en active
- 2012-09-11 MX MX2014012694A patent/MX365302B/es active IP Right Grant
- 2012-09-11 CN CN202010449455.7A patent/CN111991383A/zh active Pending
- 2012-09-11 WO PCT/US2012/054673 patent/WO2013158145A1/en not_active Ceased
- 2012-09-11 JP JP2015506953A patent/JP6234436B2/ja active Active
-
2014
- 2014-10-17 CL CL2014002807A patent/CL2014002807A1/es unknown
- 2014-10-19 IL IL235127A patent/IL235127A/en active IP Right Grant
- 2014-10-20 ZA ZA2014/07597A patent/ZA201407597B/en unknown
- 2014-10-27 EC ECIEPI201424561A patent/ECSP14024561A/es unknown
-
2017
- 2017-01-10 US US15/402,780 patent/US20170266143A1/en not_active Abandoned
- 2017-04-20 CY CY20171100449T patent/CY1118838T1/el unknown
- 2017-05-30 CL CL2017001375A patent/CL2017001375A1/es unknown
- 2017-08-25 US US15/687,136 patent/US20180015058A1/en not_active Abandoned
- 2017-10-24 JP JP2017204831A patent/JP6637941B2/ja active Active
- 2017-11-26 IL IL255918A patent/IL255918B/en active IP Right Grant
-
2018
- 2018-01-09 AU AU2018200163A patent/AU2018200163B2/en active Active
- 2018-05-15 US US15/980,431 patent/US20180263938A1/en not_active Abandoned
-
2019
- 2019-03-15 AU AU2019201811A patent/AU2019201811B2/en active Active
- 2019-08-19 JP JP2019149843A patent/JP2019219413A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019201811B2 (en) | Methods of therapeutic monitoring of phenylacetic acid prodrugs | |
| KR102019000B1 (ko) | 질소 스캐빈징 약물들의 치료학적 모니터링 방법들 | |
| EP2922576B1 (en) | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy | |
| Sorokoumova et al. | Urine metabolic profile in rats with arterial hypertension of different genesis | |
| HK1243959B (en) | Methods of therapeutic monitoring of phenylacetic acid prodrugs | |
| HK1208380B (en) | Hpn-100 for use in the treatment of nitrogen retention disorders | |
| HK1213778B (en) | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |